Olipass올리패스
244460 · KOSDAQ · ₩244460 · 올리패스
- Market cap
- ₩13B
- Enterprise value
- ₩23B
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- 1,130.9%
- Net margin
- −531.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range0.0% from the high
₩1,651Today: ₩1,651 – ₩1,651₩1,651
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD0.0%
- 1Y0.0%
- Volume today
- —
- Traded today
- —
- Listed shares
- 8,125,511
- EPS (12 months)
- −₩988
- Earnings yield −59.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Olipass stock overview
Olipass (올리패스, KRX: 244460) is listed on KOSDAQ, in the Biotech & Pharma sector. OliPass develops RNA therapeutics based on its proprietary OliPass PNA (OPNA) platform, which is designed to bind pre-mRNA inside cells and modulate gene expression through exon skipping. Its shares closed at ₩1,651 on Oct 30, 2026, unchanged on the day, giving it a market value of ₩13B.
Key facts
- Market cap
- ₩13B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 30, 2026
- Main business
- OliPass develops RNA therapeutics based on its proprietary OliPass PNA (OPNA) platform, which is designed to bind pre-mRNA inside cells and modulate gene expression through exon skipping.
Quick answers about Olipass
- What does Olipass do?
- OliPass develops RNA therapeutics based on its proprietary OliPass PNA (OPNA) platform, which is designed to bind pre-mRNA inside cells and modulate gene expression through exon skipping. Its lead candidate, OLP-1002, is a non-opioid pain treatment targeting the SCN9A gene and has completed early-stage clinical trials in the UK and Australia, with additional pipeline work in ALS. The company's revenue comes mainly from technology license fees and joint research with pharmaceutical partners, and it also sells some PDRN and cosmetic products.
- What is the market cap of Olipass?
- The market capitalisation of Olipass was ₩13B at the close on Oct 30, 2026.
- Who are the largest shareholders of Olipass?
- According to the latest official filings, the largest reported holders are GenoCure (41.54%, as of Dec 10, 2025); Bateri (12.08%, as of Jul 31, 2026); Star & Partners (6.53%, as of Oct 23, 2024).
- When is the next earnings report from Olipass?
- Korean companies rarely announce results dates in advance. Based on when Olipass filed the same report in past years, its next 3q results is expected between Nov 11, 2026 and Nov 14, 2026.
Company profile
OliPass develops RNA therapeutics based on its proprietary OliPass PNA (OPNA) platform, which is designed to bind pre-mRNA inside cells and modulate gene expression through exon skipping. Its lead candidate, OLP-1002, is a non-opioid pain treatment targeting the SCN9A gene and has completed early-stage clinical trials in the UK and Australia, with additional pipeline work in ALS. The company's revenue comes mainly from technology license fees and joint research with pharmaceutical partners, and it also sells some PDRN and cosmetic products.
Written by AI from the company's latest annual report.
- Korean name
- 올리패스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김태현
- Founded
- Nov 2006
- Listed
- Sep 2019
- Listed shares
- 8,125,511
- Fiscal year ends
- Month 12
- Website
- www.olipass.com
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- [Amended] Commencement of Rehabilitation Proceedings DecisionOct 12, 2026
- Amended: Half-year report (Jun 2026)Oct 7, 2026
- [Amended] Commencement of Rehabilitation Proceedings DecisionSep 10, 2026
- Other Market Notice (Non-Implementation of Procedures Following Addition of Grounds for Substantive Review of Listing Eligibility)Aug 14, 2026
- [Attachment Added] Confirmation of Facts Such as Adverse Opinion or Disclaimer in Semi-Annual Review (Audit) Report, Including Capital Impairment Ratio of 50% or More or Equity Below ₩1BAug 14, 2026
Titles in Korean until English translations are added.
Also known as: Olipass / 올리패스 / 244460 / KRX:244460
Source: KRX statistical information